Strategic partnerships Pharmaron has active high-profile collaborations with global players such as Eli Lilly and CN Bio, signaling openness to long-term, multi-site programs and co-developed technologies that sales teams can leverage to propose expanded CRO/CDMO engagements and multi-year service agreements.

Global expansion With significant investments in mRNA, viral vector, and CGT manufacturing facilities across the UK and Europe, Pharmaron is expanding capacity for advanced therapies, presenting upsell opportunities in biologics, CGT, and translational services for clients pursuing international development and commercial-scale production.

Diverse modality expertise Pharmaron covers small molecules, biologics, radiochemistry, and cell and gene therapy, enabling cross-sell to customers at different stages of discovery through clinical development, including API manufacturing, formulation, and radiation labeling services.

Broad service footprint End-to-end capabilities across chemistry, biology, DMPK, toxicology, pharmacology, CMC, and clinical development position Pharmaron as a one-stop shop, allowing sales teams to target sponsors seeking integrated solutions and streamlined vendor management.

Strategic access and growth Recent leadership changes and expansion into organ-on-a-chip collaborations with CN Bio, plus ongoing partnerships with major pharma, indicate a momentum of strategic growth and an opportunity to position Pharmaron for larger, multi-year deals in early discovery through late-stage development.